

ACE Inhibitors Market Assessment, Drugs [Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others], By Route of Administration [Oral and Injectable], By Indication [Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease, Others], By End-user [Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, E-commerce Websites], By Region, Opportunities and Forecast, 2017-2031F

<https://marketpublishers.com/r/AF19679C2C3CEN.html>

Date: March 2025

Pages: 228

Price: US\$ 4,500.00 (Single User License)

ID: AF19679C2C3CEN

Abstracts

Global ACE inhibitors market size was valued at USD 7.16 billion in 2023 and is expected to reach USD 10.86 billion in 2031, with a CAGR of 5.34% for the forecast period between 2024 and 2031. The global ACE inhibitors market is driven by several factors, including the rising prevalence of cardiovascular disorders, such as hypertension, which has increased demand for cost-effective drugs. Introducing new innovative products for treating hypertension is a major factor driving the market growth. Additionally, the market is influenced by factors such as the growing awareness of the benefits of ACE inhibitors in managing various cardiovascular conditions, advancements in drug formulations, and research and development activities aimed at enhancing ACE inhibitors' efficacy and safety profiles.

ACE Inhibitors are highly beneficial in preventing death and promoting health in heart patients. The development of novel drugs by the key market players and rising awareness among patients regarding regular check-ups, such as ECG, are driving the growth of the global ACE inhibitors market. Moreover, governmental initiatives are expected to improve access to screening technologies and efficient drug developments

in developing and under-developed countries, which will increase access to ACE inhibitors in these markets.

Increasing Prevalence of Cardiovascular Patients

There has been a surge in demand for ACE Inhibitors due to rising number of cardiovascular diseases worldwide. ACE Inhibitors plays a crucial role in relaxing the veins and arteries to lower the blood pressure. Due to it, the inhibitors act as an important drug in preventing life-threatening heart condition. According to American Heart Association, around 19.1 million people died in 2020 due to cardiovascular diseases. Around 244.1 million people were affected by ischemic heart diseases globally. ACE inhibitors are highly efficient in controlling blood pressure and coronary artery diseases and prevents heart failures and heart attack. There is an increased awareness among the people regarding benefits and potential of ACE inhibitors, due to which, there has been a consistent increase in demand for ACE inhibitors globally.

ACE Inhibitors are Receiving Significant Investments from Stakeholders

With high prevalence of cardiovascular diseases, there is a high demand to invest in research and development in the medicines for management of heart diseases. ACE Inhibitors have the potential to control and prevent heart health outcomes such as strokes, ischaemic heart diseases. Due to it, pharmaceuticals companies are continuously investing and launching modern ACE inhibitors.

In February 2023, Travele Therapeutics, Inc. announced FDA approval for Filspari to reduce proteinuria in adults, who are affected by IgAN, which is a rare kidney disease. Filspari is an ACE inhibitor which has proved to be beneficial for the patients suffering from IgAN and have the potential to reduce proteinuria and further prevent kidney failure.

Government Initiatives

As the prevalence of chronic diseases is increasing globally, governments are consistently launching initiatives and policies to improve access to ACE inhibitors in developed and emerging countries. Government support for research and development in the pharmaceutical industry, including the development of ACE inhibitors, is a key factor in driving innovation and market growth. Additionally, regulatory approval process and healthcare policies can impact market dynamics and the availability of ACE inhibitors.

For instance, World Heart Vision 2030 was launched by the World Heart Federation to bring policies and programs to improve cardiovascular health and reduce cardiovascular conditions such as heart failure and heart attack. Several steps were taken under these initiatives, such as increasing awareness regarding therapeutical approaches towards heart health, research and development for efficient drug discoveries, and improved accessibility to heart care facilities.

Rapid Growth in Demand for Lisinopril Drugs

Among the drugs segment, Lisinopril holds a significant share in global ACE inhibitors market. Tremendous research and development activities and increased investments by key market players in the segment are leading to the huge demand for Lisinopril Drugs in the ACE inhibitors market. Moreover, its potential to control blood pressure by widening blood vessels is the main reason behind its increasing demand. Due to this, many key market players are including drugs in their product portfolio. In September 2023, Almatica Pharma LLC., a global leader in developing medicines for several therapy areas such as cardiovascular diseases, psychiatry, and pain management recently received FDA approval for Zestril (lisinopril), specially manufactured for managing hypertension. Supportive regulatory systems are enabling pharmaceutical companies to invest and launch drugs for these heart conditions.

North America Holds the Largest Share in the Market

North America holds the highest share of the global ACE inhibitors market. Robust healthcare infrastructure and advanced healthcare facilities are some of the factors that make North America a global leader in the healthcare market. Growing awareness about the importance and benefits of screening and early diagnosis in preventing heart related diseases is driving the demand for ACE inhibitors globally. Growing focus on preventive healthcare, along with increasing availability of healthcare professionals, further leads to growing usage of ACE inhibitors for reducing the probability of mortality due to cardiovascular disorders. With the growing prevalence of cardiovascular diseases in the USA, there is a huge demand for ACE Inhibitors in the region. For instance, according to CDC, the most common cause of death in the United States is heart disease, and over 805,000 Americans get a heart attack each year. Due to this, the demand for ACE inhibitors is expected to grow in North America.

Future Market Scenario

Global ACE inhibitors market is expected to grow in the coming years, due to multiple factors. Primarily, the increasing elderly population, which is prone to cardiovascular and other chronic diseases. It has further led to increase in demand for ACE Inhibitors to provide treatment. Rising awareness regarding the screening programs, along with increased research and developments are also contributing to the market's growth. Additionally, the market is being influenced by the growing demand for cost-effective drugs and the development of combination therapies such as ACE Inhibitors and diuretics and ACE Inhibitors and angiotensin receptor blockers. Geographically, Asia-Pacific is expected to experience the fastest growth, driven by a sizable population base, rising urbanization, and an increase in the prevalence of cardiovascular diseases.

Key Players Landscape and Outlook

In the ACE inhibitors market, public and private companies are progressively establishing initiatives, strategic partnerships, and distribution agreements, which are pivotal in propelling the global ACE inhibitors market's expansion. These alliances empower firms to adapt to each other's strengths, gain access to new markets and technologies, and pool resources for research and development endeavors. Distribution agreements enable companies to broaden their market presence at an international level.

In January 2023, AstraZeneca acquired CinCor Pharma, Inc., a biopharmaceutical company, working on novel treatments for hypertension as well as chronic kidney disease by developing medicines such as ACE inhibitors. The strategic acquisition will enable the company to enhance its portfolio for the management of cardiovascular diseases, which will further expand the company's global presence.

Contents

1. RESEARCH METHODOLOGY

2. PROJECT SCOPE & DEFINITIONS

3. EXECUTIVE SUMMARY

4. GLOBAL ACE INHIBITORS MARKET OUTLOOK, 2017-2031F

4.1. Market Size & Forecast

4.1.1. Value

4.1.2. Volume

4.2. By Drugs

4.2.1. Lisinopril

4.2.2. Ramipril

4.2.3. Enalapril

4.2.4. Benazepril

4.2.5. Fosinopril

4.2.6. Captopril

4.2.7. Moexipril

4.2.8. Others

4.3. By Route of Administration

4.3.1. Oral

4.3.2. Injectable

4.4. By Indication

4.4.1. Heart Failure

4.4.2. Hypertension

4.4.3. Diabetes

4.4.4. Heart Attack

4.4.5. Chronic Kidney Disease

4.4.6. Others

4.5. By End-user

4.5.1. Retail Pharmacy

4.5.2. Hospital Pharmacy

4.5.3. Online Pharmacy

4.5.4. E-commerce Websites

4.6. By Region

4.6.1. North America

- 4.6.2. Europe
- 4.6.3. South America
- 4.6.4. Asia-Pacific
- 4.6.5. Middle East and Africa
- 4.7. By Company Market Share (%), 2023

5. GLOBAL ACE INHIBITORS MARKET OUTLOOK, BY REGION, 2017-2031F

- 5.1. North America*
 - 5.1.1. Market Size & Forecast
 - 5.1.1.1. Value
 - 5.1.1.2. Volume
 - 5.1.2. By Drugs
 - 5.1.2.1. Lisinopril
 - 5.1.2.2. Ramipril
 - 5.1.2.3. Enalapril
 - 5.1.2.4. Benazepril
 - 5.1.2.5. Fosinopril
 - 5.1.2.6. Captopril
 - 5.1.2.7. Moexipril
 - 5.1.2.8. Others
 - 5.1.3. By Route of Administration
 - 5.1.3.1. Oral
 - 5.1.3.2. Injectable
 - 5.1.4. By Indication
 - 5.1.4.1. Heart Failure
 - 5.1.4.2. Hypertension
 - 5.1.4.3. Diabetes
 - 5.1.4.4. Heart Attack
 - 5.1.4.5. Chronic Kidney Disease
 - 5.1.4.6. Others
 - 5.1.5. By End-user
 - 5.1.5.1. Retail Pharmacy
 - 5.1.5.2. Hospital Pharmacy
 - 5.1.5.3. Online Pharmacy
 - 5.1.5.4. E-commerce Websites
 - 5.1.6. United States*
 - 5.1.6.1. By Drugs
 - 5.1.6.1.1. Lisinopril

- 5.1.6.1.2. Ramipril
 - 5.1.6.1.3. Enalapril
 - 5.1.6.1.4. Benazepril
 - 5.1.6.1.5. Fosinopril
 - 5.1.6.1.6. Captopril
 - 5.1.6.1.7. Moexipril
 - 5.1.6.1.8. Others
 - 5.1.6.2. By Route of Administration
 - 5.1.6.2.1. Oral
 - 5.1.6.2.2. Injectable
 - 5.1.6.3. By Indication
 - 5.1.6.3.1. Heart Failure
 - 5.1.6.3.2. Hypertension
 - 5.1.6.3.3. Diabetes
 - 5.1.6.3.4. Heart Attack
 - 5.1.6.3.5. Chronic Kidney Disease
 - 5.1.6.3.6. Others
 - 5.1.6.4. By End-user
 - 5.1.6.4.1. Retail Pharmacy
 - 5.1.6.4.2. Hospital Pharmacy
 - 5.1.6.4.3. Online Pharmacy
 - 5.1.6.4.4. E-commerce Websites
 - 5.1.7. Canada
 - 5.1.8. Mexico
- *All segments will be provided for all regions and countries covered
- 5.2. Europe
 - 5.2.1. Germany
 - 5.2.2. France
 - 5.2.3. Italy
 - 5.2.4. United Kingdom
 - 5.2.5. Russia
 - 5.2.6. Netherlands
 - 5.2.7. Spain
 - 5.2.8. Turkey
 - 5.2.9. Poland
 - 5.3. South America
 - 5.3.1. Brazil
 - 5.3.2. Argentina
 - 5.4. Asia Pacific

- 5.4.1. India
- 5.4.2. China
- 5.4.3. Japan
- 5.4.4. Australia
- 5.4.5. Vietnam
- 5.4.6. South Korea
- 5.4.7. Indonesia
- 5.4.8. Philippines
- 5.5. Middle East & Africa
 - 5.5.1. Saudi Arabia
 - 5.5.2. UAE
 - 5.5.3. South Africa

6. MARKET MAPPING, 2023

- 6.1. By Drugs
- 6.2. By Route of Administration
- 6.3. By Indication
- 6.4. By End-user
- 6.5. By Region

7. MACRO ENVIRONMENT AND INDUSTRY STRUCTURE

- 7.1. Supply Demand Analysis
- 7.2. Import Export Analysis
- 7.3. Value Chain Analysis
- 7.4. PESTEL Analysis
 - 7.4.1. Political Factors
 - 7.4.2. Economic System
 - 7.4.3. Social Implications
 - 7.4.4. Technological Advancements
 - 7.4.5. Environmental Impacts
 - 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
- 7.5. Porter's Five Forces Analysis
 - 7.5.1. Supplier Power
 - 7.5.2. Buyer Power
 - 7.5.3. Substitution Threat
 - 7.5.4. Threat from New Entrant
 - 7.5.5. Competitive Rivalry

8. MARKET DYNAMICS

- 8.1. Growth Drivers
- 8.2. Growth Inhibitors (Challenges and Restraints)

9. REGULATORY FRAMEWORK AND INNOVATION

- 9.1. Clinical Trials
- 9.2. Patent Landscape
- 9.3. Regulatory Approvals
- 9.4. Innovations/Emerging Technologies

10. KEY PLAYERS LANDSCAPE

- 10.1. Competition Matrix of Top Five Market Leaders
- 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
- 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
- 10.4. SWOT Analysis (For Five Market Players)
- 10.5. Patent Analysis (If Applicable)

11. PRICING ANALYSIS

12. CASE STUDIES

13. KEY PLAYERS OUTLOOK

- 13.1. Novartis AG
 - 13.1.1. Company Details
 - 13.1.2. Key Management Personnel
 - 13.1.3. Products & Services
 - 13.1.4. Financials (As reported)
 - 13.1.5. Key Market Focus & Geographical Presence
 - 13.1.6. Recent Developments
- 13.2. Pfizer Inc.
- 13.3. AstraZeneca Plc.
- 13.4. Sanofi Winthrop Industries
- 13.5. Boehringer Ingelheim International GmbH
- 13.6. Merck & Co., Inc.

13.7. Lupin Pharmaceutical, Inc.

13.8. Sun Pharmaceutical Industries Limited

13.9. Bayer AG

13.10. Cipla Limited

13.11. AbbVie Inc.

13.12. Bristol-Myers Squibb Pharmaceuticals Limited

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. STRATEGIC RECOMMENDATIONS

15. ABOUT US & DISCLAIMER

I would like to order

Product name: ACE Inhibitors Market Assessment, Drugs [Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others], By Route of Administration [Oral and Injectable], By Indication [Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease, Others], By End-user [Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, E-commerce Websites], By Region, Opportunities and Forecast, 2017-2031F

Product link: <https://marketpublishers.com/r/AF19679C2C3CEN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AF19679C2C3CEN.html>